We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

THERMO FISHER SCIENTIFIC

  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Calprotectin Levels Vary When Measured in Different Matrices for COVID-19

By LabMedica International staff writers
Posted on 28 Dec 2021
Print article
Image: The Phadia 200 instrument is capable of diagnostic testing menu of more than 700 different ImmunoCAP and EliA tests to aid in the diagnosis of allergy and autoimmune diseases (Photo courtesy of Thermo Fisher Scientific)
Image: The Phadia 200 instrument is capable of diagnostic testing menu of more than 700 different ImmunoCAP and EliA tests to aid in the diagnosis of allergy and autoimmune diseases (Photo courtesy of Thermo Fisher Scientific)
Several risk scores, diagnostic imaging and biomarkers have been evaluated and compared to help predict severe complications and outcome in COVID-19 patients. Nevertheless, early prediction of COVID-19 severity remains difficult, emphasizing the need for additional biomarkers in daily practice.

Calprotectin (CLP) is typically expressed and secreted by neutrophils, monocytes, and activated macrophages, but can also be expressed and secreted by other cell lines including but not limited to dendritic cells, endothelial cells, keratinocytes and squamous mucosal epithelium. Circulating CLP (cCLP) has gained recent attention as a biomarker of neutrophil-related inflammation and chronic inflammatory disorders.

Medical Laboratory Scientists at the OLV Hospital (Aalst, Belgium) prospectively included patients with primary diagnosis of SARS-CoV-2, confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR)) who presented at the emergency department (ED) requiring hospitalization. One hundred and thirty-six SARS-CoV-2 positive patients were included (70 hospitalized at a non-ICU ward; 66 at an ICU ward), next to 40 SARS-CoV-2 negative control patients (20 non-ICU; 20 CV-ICU).

The primary biomarkers of interest concerning the inflammatory response to COVID-19 were cCLP (measured in heparin, EDTA and citrate plasma and serum), C-reactive protein (CRP), Interleukin-6 (IL-6), lactate dehydrogenase (LDH) and procalcitonin (PCT). After routine laboratory analysis, including CRP, LDH and PCT analysis, was performed on blood samples taken at the ED, aliquots of serum, heparin plasma, EDTA plasma and citrate plasma were stored at -20 °C. Batch analyses of cCLP using the EliA Calprotectin 2 assay on a Phadia 200 instrument (Thermo Fisher Scientific, Waltham, MA, USA) and IL-6 (Elecsys IL-6 on cobas c801, Roche Diagnostics, Rotkreuz, Switzerland) were performed on stored aliquots.

The investigators reported that for the 136 COVID-19 patients, cCLP levels were higher compared to the respective control populations, with significantly higher cCLP levels in serum and heparin than in EDTA or citrate. Higher cCLP levels were obtained for COVID-19 patients with i) severe/critical illness (n=70), ii) ICU admission (n=66) and iii) need for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) (n=25), but iv) not in patients who deceased within 30 days (n=41).

The authors concluded that cCLP has a high power to discriminate severe or critical COVID-19 cases versus patients presenting with asymptomatic, mild or moderate disease, to predict the need for ICU admission and the need for mechanical ventilation or ECMO. The study was published on December 14, 2021 in the journal Clinica Chimica Acta.

Related Links:
OLV Hospital
Thermo Fisher Scientific
Roche Diagnostics


New
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test
New
Silver Supplier
CLIA Microwell Strip Luminometer
LumiStat 4900
New
PLGF ELISA Kit
Placental Growth Factor ELISA
New
Microbiology IVD System
MALDI Biotyper Sirius One

Print article

Channels

Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.